Huntsman Cancer Institute at the University of Utah | Strategic Alliance Partners

Douglas W. Sborov, MD, MS, discusses key data and therapeutic developments that have reshaped the treatment of patients with newly diagnosed and relapsed/refractory multiple myeloma.

Deborah M. Stephens, DO, discusses her approach to treating a patients with chronic lymphocytic leukemia, how CAR T-cell therapy may fit into the treatment paradigm, and the numerous trials that have shown promise in this space.

Deborah M. Stephens, DO, discusses early intervention with targeted agents to improve outcomes in patients with high-risk chronic lymphocytic leukemia.

Deborah M. Stephens, DO, discusses the phase 3 ELEVATE-RR trial comparing the safety and efficacy of acalabrutinib with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Heloisa P. Soares, MD, PhD, discusses the standard of care in metastatic pancreatic cancer.

Heloisa P. Soares, MD, PhD, discusses advances in the management of pancreatic neuroendocrine tumors.

The combination of atezolizumab and cabozantinib elicited encouraging responses, marked by an unprecedented disease control rate, in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer, but most strikingly in patients with high-risk features.

Douglas W. Sborov, MD, MS, discusses supportive care approaches for selinexor-associated toxicities in multiple myeloma.

Neeraj Agarwal, MD, discusses the adverse effects associated with belzutifan in patients with renal cell carcinoma.

Heloisa P. Soares, MD, PhD, discusses recent developments in NETS, pancreatic cancer, and GEJ tumors, as well as sequencing strategies aimed at improving patient outcomes across GI cancers.

Douglas W. Sborov, MD, MS, discusses management strategies for bispecific antibody–related adverse effects in multiple myeloma.

Douglas W. Sborov, MD, MS, discusses mitigating toxicities associated with monoclonal antibodies in multiple myeloma.

Douglas W. Sborov, MD, MS, discusses the toxicities associated with novel therapies in multiple myeloma.

Neeraj Agarwal, MD, discusses the efficacy of intensified androgen deprivation therapy in patients with newly diagnosed, metastatic, hormone-sensitive prostate cancer.

Sonam Puri, MD, discusses recent research on clinically relevant biomarkers in small cell lung cancer. 

Sonam Puri, MD, discusses the rationale to evaluate the real-world multiomic characterization of small cell lung cancer subtypes.

Dr. Masten reflects on the main challenges that arose during the COVID-19 lockdown with regard to surgery in patients with breast cancer, the steps that were taken as the lockdown started to lift, and the changes that have been made with regard to managing patients around the time of surgery and in the operating room.

Christos Vaklavas, MD, discusses the progress that has been made in metastatic HR-positive, HER2-negative breast cancer and potential pathways forward for therapeutic sequencing.

Cindy B. Matsen, MD, discusses the potential effects of the decrease in screening for patients with breast cancer during the coronavirus disease 2019 pandemic.

Neeraj Agarwal, MD, discusses the role of docetaxel in the frontline setting, the emergence of novel hormonal agents in the paradigm, and efforts being made with combination regimens to potentially treat patients with resistant disease.

Neeraj Agarwal, MD, discusses remaining challenges with abiraterone acetate in metastatic castration-sensitive prostate cancer.

Neeraj Agarwal, MD, remaining challenges in metastatic castration-sensitive prostate cancer.

Neeraj Agarwal, MD, discusses unmet needs in metastatic hormone-sensitive prostate cancer.

Neeraj Agarwal, MD, discusses the safety profile of olaparib in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, director of the Genitourinary Oncology Program, Oncology Division, professor of medicine, physician, and investigator, at Huntsman Cancer Institute, discusses data with the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal, MD, discusses the tolerability of apalutamide in metastatic castration-sensitive prostate cancer.

Neeraj Agarwal, MD, discusses the implications of the PFS2 data from the TITAN trial in metastatic castration-sensitive prostate cancer.

Neeraj Agarwal, MD, discusses data from a posthoc analysis of the phase III TITAN trial in patients with metastatic castration-sensitive prostate cancer.

Neeraj Agarwal, MD, discusses the safety profile ofcabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, discusses the impact of the TITAN trial in metastatic castration-sensitive prostate cancer.